The new anti-idiotypic antibodies are specific to pertuzumab, guselkumab, canakinumab, belimumab and emicizumab. According to the company, these additions support bioanalytical assays designed for pharmacokinetic and anti-drug antibody testing, essential in both innovator and biosimilar drug development.

The extended SpyCatcher range now includes the Human IgM-FcSpyCatcher reagent, designed to enable rapid switching of antibody formats at the protein level. This new reagent facilitates the spontaneous formation of pentameric and hexameric IgMs and has been validated for use in ELISA, western blotting and precipitation assays. It is also compatible with Bio-Rad’s recombinant HuCAL antibodies.

“Bio-Rad’s leading portfolio of monoclonal anti-idiotypic antibodies is extensive; with 45 different specificities and more than 250 antibodies, we are providing greater flexibility for the development of highly selective and highly sensitive bioanalytical assays,” said Hilary Mavor, marketing director, life science group, Bio-Rad. “With the addition of the new SpyCatcher protein, we are continuing to deliver new and innovative bioanalysis tools for both our custom and catalog antibody customers, driving advances in antibody drug discovery.”

The new reagents are approved for in vitro research use. The anti-idiotypic antibodies are also authorised for use in commercial in vitro testing services, including preclinical and clinical drug development, biosimilar development, and patient monitoring.

By expanding its bioanalytical product lines, Bio-Rad is responding to growing demand for specialized tools that can streamline antibody drug discovery workflows and enhance assay reproducibility across a range of biologics.